- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04337684
Long Term Follow-up on Menkes Disease Patients
Long Term Follow-Up and Collection of Historical Control Data on Menkes Disease Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
- To provide additional clinical and safety data on long term following administration of Copper Histidinate treatment in patients treated with Copper Histidinate under Protocols 09-CH-0059 and 90-CH0149 and untreated patients previously identified and/or enrolled in Protocol 09-CH-0059.
- To provide additional Historical Control data on Menkes disease patients.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10014
- Cyprium Study Team
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
- Any subject previously identified and/or enrolled in either Protocols 09-CH-0059 or 90-CH-0149.
- Any new untreated Menkes disease patient born after 1999.
Description
Inclusion Criteria:
- The subject must have been previously identified and/or enrolled under Protocols 09-CH-0059 or 90-CH-0149; or An untreated Menkes disease patients for whom data collection is incomplete under Protocols 09-CH-0059 (Amendment M); or Other untreated Menkes disease patients.
- Must sign and date an informed consent form by parent or legal guardian for this study prior to any assessment being done in this study. If the patient is > 18 years of age, the patient must sign the informed consent.
- Male or female, aged 0 to < 65 years of age.
Exclusion Criteria:
- Unwillingness/unable to participate in the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Historical Control
|
|
Treated with Copper Histidinate
|
Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data. During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long Term Follow-Up on Survival
Time Frame: 12/01/2019 - 12/31/2022
|
The primary outcome measure will be overall survival.
|
12/01/2019 - 12/31/2022
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Metal Metabolism, Inborn Errors
- Hair Diseases
- Menkes Kinky Hair Syndrome
Other Study ID Numbers
- CYP-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menkes Disease
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Cyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMenkes Disease | Occipital Horn Syndrome | Unexplained Copper DeficiencyUnited States
-
Kunming Hope of Health HospitalTerminatedMenkes SyndromeChina
-
Stephen G. Kaler, MDRecruitingMenkes Disease | Occipital Horn SyndromeUnited States
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Heart Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Arterial Occlusive DiseaseUnited States
Clinical Trials on Long Term Follow-Up
-
Ukraine Association of BiobankActive, not recruitingDiabete Type 2 | Mesenchymal Stem CellUkraine
-
City of Hope Medical CenterActive, not recruiting
-
Blue Note TherapeuticsEnrolling by invitation
-
Shandong UniversityRecruitingPolycystic Ovary SyndromeChina, United States, Brazil, Singapore, Sweden, Turkey
-
Miltenyi Biomedicine GmbHNot yet recruiting
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Princesse GraceCompletedFamily Caregivers | Alzheimer's Dementia (AD)Monaco
-
Abbott Medical DevicesCompletedAdvanced Refractory Left Ventricular Heart FailureGermany, Canada, Austria, Czechia, Kazakhstan, Australia
-
REGENXBIO Inc.Enrolling by invitation
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States